RT Journal Article
SR Electronic
T1 Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.07.21251281
DO 10.1101/2021.02.07.21251281
A1 Eduardo Cervantes-Alvarez
A1 Nathaly Limon-de la Rosa
A1 Moisés Salgado-de la Mora
A1 Paola Valdez-Sandoval
A1 Mildred Palacios-Jiménez
A1 Fátima Rodriguez-Alvarez
A1 Brenda I. Vera-Maldonado
A1 Eduardo Aguirre-Aguilar
A1 Juan Manuel Escobar-Valderrama
A1 Jorge Alanis-Mendizabal
A1 Osvely Méndez-Guerrero
A1 Farid Tejeda-Dominguez
A1 Jiram Torres-Ruíz
A1 Diana Gómez-Martín
A1 Kathryn L Colborn
A1 David Kershenobich
A1 Christene A Huang
A1 Nalu Navarro-Alvarez
YR 2021
UL http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251281.abstract
AB BACKGROUND Prognostic biomarkers are needed to identify patients at high-risk for severe COVID-19. Galectin-3 is known to drive neutrophil infiltration and release of pro-inflammatory cytokines contributing to airway inflammation.METHODS In this prospective cohort, we assessed galectin-3 levels in 156 hospitalized patients with confirmed COVID-19. COVID-19 patients were diagnosed as either critical (>50% lung damage) or moderate (<50% of lung damage) based on computerized tomography. Patients who required invasive mechanical ventilation (IMV) and/or died during hospitalization were categorized as having a severe outcome, and a non-severe outcome if they were discharged and none of the former occurred.RESULTS Elevated serum galectin-3 was significantly higher in critical patients compared to moderate ones (35.91 ± 19.37 ng/mL vs. 25 ± 14.85 ng/mL, p<0.0001). Patients who progressed to a severe outcome including IMV and/or in-hospital death, presented higher galectin-3 levels (41.17 ng/mL [IQR 29.71 – 52.25] vs. 23.76 ng/mL [IQR 15.78 – 33.97] compared to those of a non-severe outcome, p<0.0001). Galectin-3 discriminated well between those with severe and non-severe outcome, with an AUC of 0.75 (95% CI 0.67 – 0.84, p<0.0001) and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Additionally, the combination of galectin-3, CRP and albumin, significantly improved its individual predicting ability with an AUC 0.84 (95% CI 0.77 – 0.91, p<0.0001).CONCLUSION Circulating galectin-3 levels can be used to predict severe outcomes in COVID-19 patients, including the requirement of mechanical ventilation and/or death, regardless of the initial severity of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the grant #312285 from Consejo Nacional de Ciencia y Tecnología (CONACYT)-México (N.N.A.) and University of Colorado Anschutz Medical Campus Department of Surgery Academic Enrichment Fund (C.A.H.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán's Research Ethics Committee (No. GAS-3385-20-20-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materialsARDSAcute respiratory distress syndromeCOVID-19Coronavirus disease 2019CRPC-Reactive proteinCTComputerized tomographyELISAEnzyme-linked immunosorbent assayIMVInvasive mechanical ventilationRT-PCRReal-time reverse transcriptase-polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus-2